Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

Perrigo appoints Gerresheimer’s Uwe Rohrhoff as CEO

He succeeds John Hendrickson, who resigns as CEO and board member

2018 by Darwin

Our industry’s evolution can’t be predicted, but it can be foreseen

Engagement Table

Discover who are the most engaging Pharma companies on Twitter

With engagement such a key performance metric we first created a weighted formula, incorporating likes, retweets and replies, which produced an engagement score for each account.

An agency called Owen

- PMLiVE

Sanifit appoints CFO

Cris Calsada joins the biopharma from Ambrx

- PMLiVE

Novartis joins biosimilar Humira push in US

Pharma giant hopes its candidate will follow in the footsteps of Amgen’s Amjevita and BI’s Cyltezo

Shire wins FDA approval for haemophilia dosing software

The web-based myPKFiT supports the pharma firm's Advate treatment

- PMLiVE

UK biotech Vaccitech raises £20m for universal flu shot

Aims to develop a vaccine targeting proteins in the core of the virus

International digital pharma marketing: 10 common problems

Your digital marketing challenges are probably shared by peers in other departments and companies. The good news is that such problems often have simple solutions, or can be avoided completely...

Anthill Agency

Leading NHS suppliers highlighted in shortlist for new HSJ awards

The finalists for the first HSJ Healthcare Partnership Awards have been announced. The awards serve to recognise and celebrate those suppliers who work in partnerships with the NHS to drive...

Wilmington Healthcare

- PMLiVE

Shire claims EU approval for haemophilia A drug Adynovi

The drug will battle Bayer’s Kovaltry and Sobi's Elocta in a bid to capture market share

- PMLiVE

AZ and Merck & Co get FDA breast cancer nod for Lynparza

It becomes the first PARP inhibitor to be approved outside ovarian cancer

Lilly bolsters its oncology team

Kimberly Blackwell is appointed VP early phase development, immuno-oncology

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links